LITS - Lite Strategy • Financials

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
06/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2024	65	15	-	27%	2.7	33	54%	-38	-	-53	-0	-12	-53	0	-12	66%	-
06/2025	0	-17	-	0%	L	17	L	-18	-	-21	0	0	-21	0	0	-	-
06/2026	0	-67	-	0%	L	42	L	-6	-	-10	0	92	-10	-5	0	-	-

To see all financials—including updated, you must be Premium.